Pub Date : 2025-12-06DOI: 10.1016/j.jagp.2025.12.001
Robert H. Pietrzak Ph.D., M.P.H. , Peter J. Na M.D., M.P.H. , Yen Ying Lim Ph.D.
{"title":"Commentary: The Effect of Stress on All-Cause Dementia: A Longitudinal Analysis from the Australian Longitudinal Study on Women’s Health","authors":"Robert H. Pietrzak Ph.D., M.P.H. , Peter J. Na M.D., M.P.H. , Yen Ying Lim Ph.D.","doi":"10.1016/j.jagp.2025.12.001","DOIUrl":"10.1016/j.jagp.2025.12.001","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 281-283"},"PeriodicalIF":3.8,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145852203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-06DOI: 10.1016/j.jagp.2025.11.020
Chenlei Sun Ph.D. , Ke Meng Ph.D. , Xiaomeng Zhu Ph.D.
{"title":"Music Listening as a Low-Risk Adjunct to Delirium Prevention: Translating Evidence to the Ward","authors":"Chenlei Sun Ph.D. , Ke Meng Ph.D. , Xiaomeng Zhu Ph.D.","doi":"10.1016/j.jagp.2025.11.020","DOIUrl":"10.1016/j.jagp.2025.11.020","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 397-398"},"PeriodicalIF":3.8,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-05DOI: 10.1016/j.jagp.2025.12.003
Jiska Cohen-Mansfield Ph.D.
Objectives
Group activities for persons living with dementia (PLwD) can enhance their well-being, mental health, and affect; however, little is known about how activity type influences outcomes. This study examines the relative impact of activity type on well-being within the context of Enhanced Group Activity Kits (EGAKs).
Design
This is a secondary analysis of a stepped wedge clustered trial introducing EGAKs sequentially across settings.
Settings
Six nursing care units and four senior day center units in Israel.
Participants
One hundred fifteen PLwD who resided in or attended these settings.
Intervention
Forty seven EGAK-facilitated group activities in eight categories, including singing, creative arts, reading and discussion, and travel around the world, led by staff members.
Measurements
Research observers and activity leaders independently rated participants’ responses via the group observational measurement of engagement, from which the well-being index was derived. Mixed models analyses compared well-being across categories and within categories, controlling for participants’ cognitive function.
Results
All 47 EGAKs yielded maximum well-being scores for at least one participant. Significant differences emerged across categories: physical exercise, creative arts, singing, and Jewish texts reading/discussion achieved the highest well-being, whereas travel around the world and art history elicited the lowest. Within-category analyses showed significant variations within six of the eight categories. Correspondingly, the ranking of mean well-being for some kits diverged from others within their category.
Conclusions
While certain categories consistently promoted well-being, effectiveness depended on activity characteristics, such as personal relevance and cognitive accessibility. These findings suggest that tailoring activity content and delivery may be more important than activity type in enhancing well-being for PLwD.
{"title":"Which Type of Group Activity has the Greatest Impact on the Well-Being of Persons With Dementia? An Exploration of a Study of Enhanced Group Activity Kits","authors":"Jiska Cohen-Mansfield Ph.D.","doi":"10.1016/j.jagp.2025.12.003","DOIUrl":"10.1016/j.jagp.2025.12.003","url":null,"abstract":"<div><h3>Objectives</h3><div>Group activities for persons living with dementia (PLwD) can enhance their well-being, mental health, and affect; however, little is known about how activity type influences outcomes. This study examines the relative impact of activity type on well-being within the context of Enhanced Group Activity Kits (EGAKs).</div></div><div><h3>Design</h3><div>This is a secondary analysis of a stepped wedge clustered trial introducing EGAKs sequentially across settings.</div></div><div><h3>Settings</h3><div>Six nursing care units and four senior day center units in Israel.</div></div><div><h3>Participants</h3><div>One hundred fifteen PLwD who resided in or attended these settings.</div></div><div><h3>Intervention</h3><div>Forty seven EGAK-facilitated group activities in eight categories, including singing, creative arts, reading and discussion, and travel around the world, led by staff members.</div></div><div><h3>Measurements</h3><div>Research observers and activity leaders independently rated participants’ responses via the group observational measurement of engagement, from which the well-being index was derived. Mixed models analyses compared well-being across categories and within categories, controlling for participants’ cognitive function.</div></div><div><h3>Results</h3><div>All 47 EGAKs yielded maximum well-being scores for at least one participant. Significant differences emerged across categories: physical exercise, creative arts, singing, and Jewish texts reading/discussion achieved the highest well-being, whereas travel around the world and art history elicited the lowest. Within-category analyses showed significant variations within six of the eight categories. Correspondingly, the ranking of mean well-being for some kits diverged from others within their category.</div></div><div><h3>Conclusions</h3><div>While certain categories consistently promoted well-being, effectiveness depended on activity characteristics, such as personal relevance and cognitive accessibility. These findings suggest that tailoring activity content and delivery may be more important than activity type in enhancing well-being for PLwD.</div></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 337-347"},"PeriodicalIF":3.8,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1016/j.jagp.2025.08.009
David L. Coulter M.D.
{"title":"Lost and Found: A 78th Birthday Meditation","authors":"David L. Coulter M.D.","doi":"10.1016/j.jagp.2025.08.009","DOIUrl":"10.1016/j.jagp.2025.08.009","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 1","pages":"Pages 144-145"},"PeriodicalIF":3.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-26DOI: 10.1016/S1064-7481(25)00514-7
{"title":"Information for Subscribers","authors":"","doi":"10.1016/S1064-7481(25)00514-7","DOIUrl":"10.1016/S1064-7481(25)00514-7","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 1","pages":"Page A1"},"PeriodicalIF":3.8,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145594787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-23DOI: 10.1016/j.jagp.2025.11.012
Stephanie Yarnell M.D., Ph.D , Luming Li M.D., M.H.S. , Brian MacGrory MB BCh BAO, M.H.S., MRCP , Louis Trevisan M.D. , Paul Kirwin M.D.
{"title":"Corrigendum to “Substance use disorders in later life: a review and synthesis of the literature of an emerging public health concern” Am J Geriatr Psychiatry, 2020, 28(2): 226–236","authors":"Stephanie Yarnell M.D., Ph.D , Luming Li M.D., M.H.S. , Brian MacGrory MB BCh BAO, M.H.S., MRCP , Louis Trevisan M.D. , Paul Kirwin M.D.","doi":"10.1016/j.jagp.2025.11.012","DOIUrl":"10.1016/j.jagp.2025.11.012","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Page 267"},"PeriodicalIF":3.8,"publicationDate":"2025-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reflections on a Study of Low-Dose Agomelatine as Add-on for Agitation in Alzheimer’s Disease","authors":"Sumedha Saha M.B.B.S., Skarma Spalzang M.D., Susanta Kumar Padhy M.D., Arpit Parmar M.D., D.M.","doi":"10.1016/j.jagp.2025.11.011","DOIUrl":"10.1016/j.jagp.2025.11.011","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 3","pages":"Pages 405-406"},"PeriodicalIF":3.8,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-12DOI: 10.1016/j.jagp.2025.11.006
Rajesh R. Tampi M.D., M.S., D.F.A.P.A., D.F.A.A.G.P.
{"title":"Dronabinol for Agitation in Alzheimer’s Disease","authors":"Rajesh R. Tampi M.D., M.S., D.F.A.P.A., D.F.A.A.G.P.","doi":"10.1016/j.jagp.2025.11.006","DOIUrl":"10.1016/j.jagp.2025.11.006","url":null,"abstract":"","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Pages 180-182"},"PeriodicalIF":3.8,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-10DOI: 10.1016/j.jagp.2025.10.011
Paul B. Rosenberg M.D. , Halima Amjad M.D., M.P.H., Ph.D. , Haroon Burhanullah M.D. , Milap Nowrangi M.D. , Ryan Vandrey Ph.D. , Mersania Jn Pierre B.A. , John D. Outen M.S. , Meghan Schultz R.N., M.S.N , Christopher Marano M.D. , Marc Agronin M.D. , James M. Wilkins M.D., D.Phil. , David Harper Ph.D. , Todd Laffaye B.A. , Eilis Reardon B.A. , Kathryn Turner B.A. , Rosain Ozonsi B.S. , Mia Drury B.A. , Andre Nguyen B.S. , Tuna Hasoğlu M.D. , Julia Cromwell M.D. , Brent P. Forester M.D., M.Sc.
Importance
Agitation in Alzheimer’s disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.
Objective
Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.
Design
THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.
Setting
5 inpatient and outpatient academic clinical research centers in the Eastern U.S.
Participants
Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.
Interventions
3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.
Main Outcomes and Measures
Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.
Results
The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was −0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at −1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of ‘as-needed’ lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.
Conclusions and Relevance
Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.
Clinical Trials Registration
NCT02792257
重要性:阿尔茨海默病(AD)的躁动是患者和护理人员痛苦的一个重要来源,也是一个主要的公共卫生负担。目前的治疗方法只有适度的效果,而且许多治疗方法存在包括死亡风险在内的安全问题。我们需要新的治疗方案。有初步证据表明,四氢大麻酚(四氢大麻酚,THC)对AD躁动的安全性和有效性。目的:评价屈大麻酚(THC)减少AD患者躁动的安全性和有效性。设计:THC-AD是一项为期3周的随机平行双盲安慰剂对照临床试验,于2017年至2024年进行。背景:美国东部5个住院和门诊学术临床研究中心参与者:75名志愿者样本符合AD躁动的纳入标准(国际老年精神病学协会提供标准),神经精神量表临床医生版本躁动或攻击(NPI-C A/A)域总分为4分或以上。主要排除标准包括癫痫发作障碍、谵妄和非ad痴呆。干预措施:3周,曲大麻酚与安慰剂滴定至目标剂量10mg,每日两次。主要结局和测量:预先指定的共同主要躁动结局是匹兹堡躁动量表(PAS)和NPI-C A/A总分。结果:大多数参与者是女性,并且在基线时同时服用精神药物(抗抑郁药和抗精神病药)。研究参与者在基线时中度激动,种族背景不同(9%为黑人,11%为西班牙裔/拉丁裔/拉丁裔),并且有严重的认知障碍,由MMSE或sibb -8证明。84%完成了为期3周的试验。在临床相关程度上,屈大麻酚对两种主要结局的躁动程度均优于安慰剂。PAS下降/周的拟合臂间差异为-0.74 (SE 0.3, p = 0.015,效应量= 0.53),NPI-C A/A的下降为-1.26 (SE 0.67, p = 0.094,效应量= 0.36)。治疗组间的次要结果无差异,包括睡眠、日常生活活动、Cohen-Mansfield躁动量表(CMAI)、认知、中毒或“按需”使用劳拉西泮或曲唑酮。除嗜睡外,地大麻酚治疗与更严重的中毒或其他不良事件(ae)无关。结论及意义:辅助屈大麻酚治疗阿尔茨海默病躁动安全有效。临床试验注册:NCT02792257。
{"title":"A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease","authors":"Paul B. Rosenberg M.D. , Halima Amjad M.D., M.P.H., Ph.D. , Haroon Burhanullah M.D. , Milap Nowrangi M.D. , Ryan Vandrey Ph.D. , Mersania Jn Pierre B.A. , John D. Outen M.S. , Meghan Schultz R.N., M.S.N , Christopher Marano M.D. , Marc Agronin M.D. , James M. Wilkins M.D., D.Phil. , David Harper Ph.D. , Todd Laffaye B.A. , Eilis Reardon B.A. , Kathryn Turner B.A. , Rosain Ozonsi B.S. , Mia Drury B.A. , Andre Nguyen B.S. , Tuna Hasoğlu M.D. , Julia Cromwell M.D. , Brent P. Forester M.D., M.Sc.","doi":"10.1016/j.jagp.2025.10.011","DOIUrl":"10.1016/j.jagp.2025.10.011","url":null,"abstract":"<div><h3>Importance</h3><div>Agitation in Alzheimer’s disease (AD) is a great source of distress for patients and caregivers and a major public health burden. Current treatments are only modestly effective and many have safety issues including mortality risk. Novel therapeutic options are needed. There is preliminary evidence for the safety and efficacy of dronabinol (tetrahydrocannabinol, THC) for agitation in AD.</div></div><div><h3>Objective</h3><div>Assess the safety and efficacy of dronabinol (THC) to decrease agitation in AD.</div></div><div><h3>Design</h3><div>THC-AD was a 3-week randomized parallel double-blind placebo-controlled clinical trial, conducted between 2017 and 2024.</div></div><div><h3>Setting</h3><div>5 inpatient and outpatient academic clinical research centers in the Eastern U.S.</div></div><div><h3>Participants</h3><div>Volunteer sample of 75 participants meeting inclusion criteria for agitation of AD (International Psychogeriatric Association Provision Criteria) with Neuropsychiatric Inventory Clinician Version Agitation or Aggression (NPI-C A/A) domains total score of 4 or greater. Major exclusion criteria included seizure disorder, delirium, and non-AD dementia.</div></div><div><h3>Interventions</h3><div>3 weeks dronabinol vs. placebo titrated up to target dose of 10 mg daily in divided twice-daily.</div></div><div><h3>Main Outcomes and Measures</h3><div>Prespecified co-primary agitation outcomes were the Pittsburgh Agitation Scale (PAS) and NPI-C A/A total score.</div></div><div><h3>Results</h3><div>The majority of participants were female and were taking concomitant psychotropic medications (antidepressants and antipsychotics) at baseline. Study participants were moderately agitated at baseline, were diverse in ethnic background (9% Black, 11% Hispanic/Latina/Latino), and had severe cognitive impairment evidenced by MMSE or SIB-8. 84% completed the 3-week trial. Dronabinol decreased agitation on both primary outcomes greater than placebo to a clinically relevant extent. The fitted between-arm difference in PAS decline/week was −0.74 (SE 0.3, p = 0.015, effect size = 0.53) and for NPI-C A/A the decline was not significant at −1.26 (SE 0.67, p = 0.094, effect size = 0.36). No secondary outcomes differed between treatment arms including sleep, activities of daily living, Cohen-Mansfield Agitation Inventory (CMAI), cognition, intoxication, or use of ‘as-needed’ lorazepam or trazodone. Dronabinol treatment was not associated with greater intoxication nor with other adverse events (AEs) except for somnolence.</div></div><div><h3>Conclusions and Relevance</h3><div>Adjunctive dronabinol treatment was safe and effective for treating agitation in AD.</div></div><div><h3>Clinical Trials Registration</h3><div>NCT02792257</div></div>","PeriodicalId":55534,"journal":{"name":"American Journal of Geriatric Psychiatry","volume":"34 2","pages":"Pages 167-179"},"PeriodicalIF":3.8,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}